Additionally, gilteritinib, a small-molecular inhibitor of FLT3, was approved by the FDA for the management of relapsed or refractory (R/R) AML with FLT3 mutation according to the randomized phase III ADMIRAL study. The gene discussed is FLT3; the disease is acute myeloid leukemia.